Roche Invests $550 Million in Indianapolis Manufacturing Hub Expansion

Roche has announced a $550 million investment to expand its diagnostics manufacturing hub in Indianapolis by 2030. The focus of the expansion will be on manufacturing continuous glucose monitoring systems, creating hundreds of jobs and enhancing U.S. production capabilities.

"By expanding our manufacturing capabilities in Indianapolis, we ensure reliable access to innovative monitoring solutions for individuals living with diabetes in the U.S. and worldwide."

Brad Moore, President and CEO of Roche Diagnostics North America, said in the announcement. The investment aims to establish Indianapolis as a key site for Roche's continuous glucose monitoring solutions, which are crucial for diabetes management.

With over 38 million Americans affected by diabetes, the expansion will improve access to essential disease management tools. Indianapolis serves as the North American headquarters for Roche Diagnostics, part of the Roche Group, the world's largest biotech company.

The current campus produces approximately 5.2 billion Accu-Chek diabetes test strips annually and serves as a major distribution hub for the U.S. market and 53 other countries.

The expansion is expected to generate hundreds of highly-skilled manufacturing jobs, providing a significant boost to Indiana's economy.